The application of Southmed Pharma, which seeks to be Sinopharm's distributor in the Philippines, lacked documents such as clinical trial results and certificate of good manufacturing practice, FDA Director General Eric Domingo said.
Full Post on Source: Lacking submission to FDA delays review of Sinopharm COVID-19 jab
